The study of the neuroprotective effects of xenon in critical states was carried out in vivo, in vitro and ex vivo. In all experimental models xenon showed neuroprotective and anti-inflammatory properties by targeting key kinases and increasing the ability of neutrophils to spontaneous apoptosis. Xenon effects were also proved on isolated neutrophil cultures following exposure to septic serum and lipopolysaccharide. The clinical efficacy of xenon was evaluated in patients with post-coma impairment of consciousness (chronic critical illness) and in patients with ischemic stroke. In clinical study we showed that patients with long-term impaired consciousness who underwent xenon therapy had a much better neurological outcome compared to the group of patients who received standard intensive therapy. Similar effects were observed in patients receiving xenon sedation after stroke.

Artem Kuzovlev, 37 y.o., MD, DrSci, is anesthesia and intensive care medicine specialist, head of V.A. Negovsky research institute of general reanimatology. He has more than 240 scientific papers (incl. Web of Science 33 (H-index 6), Scopus 73 (H-index 12), 4 monographs on pathogenesis, new methods of diagnosis and treatment of critical conditions. He has been serving as an editorial board member of several reputed journals.